Health
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial – The Lancet
CoronaVac is safe and well tolerated in older adults. Neutralising antibody titresinduced by the 3 μg dose were similar to those of the 6 μg dose, and higher than…
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.
Copyright © 2021 Elsevier Inc. except certain content provided by third parties.
Privacy Policy Terms and Conditions
Continue Reading
-
Noosa News24 hours agoAustralia Post reintroduces weekend deliveries for Christmas parcel rush
-
Business21 hours agoWhat I’d buy if I had to invest $20,000 in ASX 200 shares before the weekend
-
Business23 hours agoWhy this investing expert is calling time on NAB shares
-
General19 hours agoFederal government funding extends cohealth GP services until July 2026